Integer Holdings Corp Annual Report - A Comprehensive Look at 2025

Integer Holdings Corp. delivered a robust performance in the 2025 fiscal year (January 1, 2025, to December 31, 2025). This summary distills the key insights from their annual report, offering investors a clear understanding of the company's financial health, strategic moves, and future prospects, with relevant context from 2024 and 2023.

Business Overview

Integer Holdings Corp. stands as a premier medical device outsource (MDO) manufacturer, meaning it designs, develops, and produces a wide array of medical devices and components for other companies. Serving critical therapeutic areas like cardiology, neuromodulation, orthopedics, and vascular, Integer provides advanced technologies and services, including specialized coatings and power solutions. The company partners with medical device firms worldwide, offering comprehensive solutions from initial concept to market commercialization.

2025 Financial Performance: A Strong Year of Growth

Integer Holdings achieved strong financial results in 2025, effectively executing its growth strategy:

• Revenue: Net sales reached $1.52 billion in 2025, increasing 15% from $1.32 billion in 2024. Strategic acquisitions and robust demand across its core medical device markets primarily drove this growth.
• Net Income: Net income climbed to $155 million, up from $128 million in 2024, reflecting improved operational efficiencies and higher sales volumes.
• Diluted Earnings Per Share (EPS): Diluted EPS hit $4.65, compared to $3.80 in the prior year, signaling enhanced profitability for shareholders.
• Operating Cash Flow: Integer generated robust operating cash flow of $210 million, providing ample liquidity for investments and debt management.

Management's Discussion and Analysis (MD&A) Highlights

Management's discussion delves into the strategic decisions and operational initiatives that shaped Integer's performance and future direction.

Strategic Business Evolution: Acquisitions & Divestitures

In 2025, Integer Holdings actively reshaped its portfolio, focusing on expanding its technological capabilities and market reach through key acquisitions and a strategic divestiture:

• Strategic Acquisitions:
  • Precision Coating LLC (January 7, 2025, acquired for approximately $150 million): This acquisition significantly enhances Integer's surface coating capabilities—a critical component for advanced medical devices—and strengthens customer relationships in key therapeutic areas.
  • VSi Parylene Inc. (February 28, 2025, acquired for approximately $55 million): It also adds specialized parylene coating technology, broadening Integer's offerings for miniaturized and high-performance medical components.
  • Biocoat Incorporated (December 4, 2025, acquired for approximately $110 million): Furthermore, it expands Integer's expertise in hydrophilic coatings, crucial for improving the lubricity and biocompatibility of medical devices.
  • These 2025 additions build on the successful integration of Pulse Technologies Inc. (acquired in early 2024 for ~$125 million, boosting catheter and guidewire capabilities) and InNeuroCo (acquired in late 2023 for ~$45 million, enhancing neurostimulation product lines). This consistent strategy underscores Integer's commitment to inorganic growth in high-value medical technology segments.
• Focused Divestiture:
  • In late 2024, Integer sold Electrochem Solutions Inc. for approximately $70 million. This divestiture streamlined operations and sharpened the company's focus on its core medical device components and power solutions by shedding a non-core energy storage segment.

Operational Excellence & Future Outlook

Beyond strategic portfolio changes, Integer actively pursues internal initiatives to drive efficiency and innovation:

• Operational Excellence Program: This multi-year initiative optimizes manufacturing processes, supply chain management, and quality systems to reduce costs and improve product delivery timelines. Key targets include a 15% reduction in manufacturing lead times and a 10% improvement in inventory turns by 2027.
• Strategic Reorganization and Alignment: The company completed a significant internal restructuring, better aligning its business units with key therapeutic markets. This fosters greater collaboration and accelerates product development.
• Global Manufacturing and R&D Alignment: Integer invests in consolidating and modernizing its global manufacturing footprint and research & development capabilities, supporting future product innovation and efficient scaling.

Financial Health

Integer maintained a disciplined approach to capital allocation, ensuring robust financial health.

• Liquidity and Cash Flow: The company generated strong operating cash flow of $210 million in 2025, providing significant internal funding for operations, investments, and debt service. This robust cash generation, coupled with available credit facilities, ensures ample liquidity.
• Debt Structure: Integer continues to utilize its Revolving Credit Facility (with $95 million drawn as of year-end, maturing 2028) and a Term Loan A Facility (with $480 million outstanding, maturing 2027, at a weighted average interest rate of 5.5%).
• New Convertible Senior Notes: In March 2025, Integer successfully issued $300 million in new 2.50% Convertible Senior Notes due 2030. These notes offer a lower-cost financing alternative and provide flexibility, as they are convertible into Integer common stock at an initial conversion price of $120.00 per share, subject to certain conditions. This issuance complements the existing 2028 Convertible Senior Notes, further diversifying the company's capital structure.
• Share Repurchase Program: Demonstrating confidence in its valuation and commitment to shareholder returns, the Board authorized a $75 million share repurchase program in November 2025. By year-end, Integer had repurchased approximately $50 million of its common stock, reducing the outstanding share count and potentially boosting EPS.

Future Outlook

Looking ahead, management anticipates continued positive momentum for the upcoming fiscal year.

• 2026 Outlook: Management projects continued revenue growth of 8-10% and an EPS range of $5.00-$5.30 for the 2026 fiscal year, driven by recent acquisitions and ongoing operational improvements. The company will continue its focus on strategic growth initiatives, operational excellence, and disciplined capital allocation to drive long-term shareholder value.

Competitive Position

Integer Holdings Corp. holds a strong competitive position within the highly specialized medical device outsource manufacturing market. The company leverages decades of extensive expertise in medical device design, development, and manufacturing. Its key competitive strengths include a broad portfolio of advanced technologies, robust intellectual property, and specialized capabilities in areas such as advanced coatings, power solutions, and complex component manufacturing. Integer benefits from long-standing relationships with leading medical device Original Equipment Manufacturers (OEMs), a global manufacturing footprint, and stringent quality systems that meet the demanding requirements of the medical industry. This ability to offer integrated solutions across the product lifecycle, coupled with a strategic focus on innovation and targeted acquisitions, further enhances its market leadership and differentiation.

Key Risk Factors

While Integer's outlook is positive, investors should be aware of potential risks, including:

• Economic Downturns: General economic conditions, such as inflation, interest rate fluctuations, and recessionary pressures, could impact healthcare spending and demand for medical devices.
• Regulatory Changes: The highly regulated medical device industry faces risks from evolving government regulations, shifts in reimbursement policies, and the complexities of obtaining and maintaining global product approvals.
• Supply Chain Disruptions: Global supply chain volatility, including shortages of raw materials, components, and labor, along with geopolitical events, could affect manufacturing, product delivery, and costs.
• Integration of Acquisitions: Challenges in successfully integrating acquired businesses—including achieving anticipated synergies, retaining key personnel, and managing cultural differences—could impact financial performance and operational efficiency.
• Competition: Intense competition in the medical device market from both established players and new entrants could pressure pricing, market share, and profitability.
• Cybersecurity Risks: The company faces risks related to cybersecurity breaches, data privacy, and protecting sensitive information.

In summary, Integer Holdings Corp. achieved a dynamic and financially strong 2025, strategically positioning itself for continued growth in the medical technology sector through targeted acquisitions, disciplined financial management, and a clear focus on operational excellence.